New therapeutic perspectives in HBV: when to stop NAs. (Q38174265)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24373092%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

title

New therapeutic perspectives in HBV: when to stop NAs (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24373092%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24373092%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Rafael Esteban

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24373092%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

author name string

Cristina Pérez-Cameo

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24373092%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

publication date

1 February 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24373092%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24373092%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

volume

34 Suppl 1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24373092%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

page(s)

146-153

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24373092%20AND%20SRC:MED&resulttype=core&format=json

EASL clinical practice guidelines: Management of chronic hepatitis B virus infection

3 March 2020

cites work

1 reference

Chronic hepatitis B: update 2009

21 January 2018

1 reference

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update

21 January 2018

1 reference

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update

21 January 2018

1 reference

Relapse rate and associated-factor of recurrence after stopping NUCs therapy with different prolonged consolidation therapy in HBeAg positive CHB patients

21 January 2018

1 reference

Hepatitis B surface antigen seroclearance in patients with chronic hepatitis B infection: a clinical study

21 January 2018

1 reference

Hepatitis B surface antigen seroclearance during chronic HBV infection

21 January 2018

1 reference

Chronic hepatitis B: whom to treat and for how long? Propositions, challenges, and future directions.

21 January 2018

1 reference

Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report

21 January 2018

1 reference

Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

Clinical significance and evolution of hepatic HBsAg expression in HBeAg-positive patients receiving interferon therapy

21 January 2018

1 reference

Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B.

21 January 2018

1 reference

Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B.

21 January 2018

1 reference

Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline

21 January 2018

1 reference

Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa

21 January 2018

1 reference

Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a

21 January 2018

1 reference

Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B

21 January 2018

1 reference

Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study

21 January 2018

1 reference

Guidelines for avoiding risks resulting from discontinuation of nucleoside/nucleotide analogs in patients with chronic hepatitis B.

21 January 2018

1 reference

Durability of viral response after off-treatment in HBeAg positive chronic hepatitis B.

21 January 2018

1 reference

Should lamivudine monotherapy be stopped or continued in patients infected with hepatitis B with favorable responses after more than 5 years of treatment?

21 January 2018

1 reference

Clinical course of chronic hepatitis B patients who were off-treated after lamivudine treatment: analysis of 138 consecutive patients

21 January 2018

1 reference

Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.

21 January 2018

1 reference

Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir

21 January 2018

1 reference

A comparison of efficacy and safety of 2-year telbivudine and entecavir treatment in patients with chronic hepatitis B: a match-control study.

21 January 2018

1 reference

Correlation of hepatitis B surface antigen level with response to telbivudine in naive patients with chronic hepatitis B.

21 January 2018

1 reference

Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.

21 January 2018

1 reference

Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B.

21 January 2018

1 reference

Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy

21 January 2018

1 reference

Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients

21 January 2018

1 reference

Clinical utility of quantitative HBsAg in natural history and nucleos(t)ide analogue treatment of chronic hepatitis B: new trick of old dog.

21 January 2018

1 reference

Prediction of disease reactivation in asymptomatic hepatitis B e antigen-negative chronic hepatitis B patients using baseline serum measurements of HBsAg and HBV-DNA.

21 January 2018

1 reference

Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients

21 January 2018

1 reference

Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype

21 January 2018

1 reference

Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a

21 January 2018

1 reference